Experiment: 7SFQ

SOLID-STATE NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D solid-state hNH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
2	3D solid-state hCANH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
3	3D solid-state hCONH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
4	3D solid-state hCA(CO)NH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
5	3D solid-state hCO(CA)NH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
9	3D solid-state h(CA)CB(CACO)NH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
8	3D solid-state hN(CACO)NH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
7	3D solid-state H(NCACO)NH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
10	3D solid-state h(CA)CB(CA)NH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
6	2D hNH-resolved 1H-19F REDOR	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
11	2D FF Exchange	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600
12	2D water-edited solid-state hNH	0.27 mg/uL [U-13C; U-15N; U-2H] Multidrug Resistance Protein E (EmrE), Complex with tetra(4-fluorophenyl)phosphonium, 9.5 ug/uL F4TPP, 0.44 mg/uL [U-99% 2H] d54-DMPC	bilayers	0.07 M	8.0	1 atm	285	Bruker AVANCE III 600

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	600

NMR Refinement
Method	Details	Software
molecular dynamics	The authors state that the starting model for structure calculation was 7JK8. The ligand VCJ was removed from the 7JK8 structure and re-docked using HADDOCK, under new constraints measured in the present study. The docked structures best agreeing with experiment were further refined by all-atom MD simulations in explicit lipid bilayers to generate the ensemble deposited for this study.	GROMACS

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	82
Conformers Submitted Total Number	10
Representative Model	1 (fewest violations)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	structure calculation	HADDOCK	Webserver 2.4	Alexandre Bonvin and members of the computational structural biology group, Utrecht University
2	refinement	GROMACS	2019.1	UNIVERSITY OF GRONINGEN ROYAL INSTITUTE OF TECHNOLOGY UPPSALA UNIVERSITY
3	collection	TopSpin	2.1-4.0	Bruker Biospin
5	processing	TopSpin	2.1-4.0	Bruker Biospin
4	chemical shift assignment	NMRFAM-SPARKY	1.414, 1.470	NMRFAM
6	peak picking	NMRFAM-SPARKY	1.414, 1.470	NMRFAM

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.